52 results about "Clinical effectiveness" patented technology

A reference phantom includes CT-imageable detail together with light-reflective spheres. This item can be placed on a patient table in a known location, following which the diagnostic source can be activated to detect the phantom position relative to the isocentre and camera employed to detect the PSS position. A synthetic image of the phantom can be used for comparison with the CT dataset. This allows improved correlation of the source and the patient support, enable further steps to be taken in enhancing the clinical effectiveness of the apparatus. In-use variations of the isocentre location can be corrected in real time by adjustment of the patient support. Thus, as the isocentre moves, the patient can be moved so as to track the moving isocentre. The linac arm could also be designed differently, as the existing design constraint (that isocentre movement must be limited as far as possible) could potentially be relaxed in order to achieve other aims.

The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and / or E2 and / or E1 / E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and / or clinical outcome of HCV treatment.

The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and / or E2 and / or E1 / E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and / or clinical outcome of HCV treatment.

The invention relates to a method for quantitatively analyzing a myocardium acoustic contrast image, which belongs to the technical field of medical image analysis and processing. The method comprises the following steps: determining an energy equation in optical flow calculation; constructing pyramid expressions of each frame of a myocardium acoustic contrast image sequence; calculating an optical flow field of the image sequence by adopting a searching policy from roughness to precision; selecting an ROI area of a myocardium segment; determining displacements of the selected ROI area of the myocardium segment in each frame of the myocardium acoustic contrast image sequence; determining positions of the selected ROI area of the myocardium segment in each frame of the myocardium acoustic contrast image sequence and measuring dB values of sampling points of the positions; determining unknown parameters in a quantitative analysis mathematical model of the myocardium acoustic contrast; and drawing a time-intensity curve of the myocardium acoustic contrast. The method achieves the full automation of the quantitative analysis of the myocardium acoustic contrast image and has accurate analysis result and high clinical effectiveness and objectivity.

The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and / or E1 / E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and / or clinical outcome of HCV treatment.

The invention discloses a raidx astragali particle. The radix astragali particle is prepared by a following method: the medicinal materials of the radix astragali are decocted with water and extracted twice; the medicinal materials of the radix astragali are decocted for 1.5 to 2.5hours every time; decoctions are put together and filtered; filtrate is concentrated into a clear paste with relative density of 1.20 to 1.30 (70 to 80 DEG C); auxiliary materials are added and mixed evenly; then the medicinal materials of the radix astragali and the auxiliary materials are processed by granulation, drying, sub-package and sterilization; and the raidx astragali particle is made. The radix astragali particle is prepared by the new method and the procedures of alcohol precipitation is reduced. That decoction time is changed is beneficial to the dissolution and preservation of effective components. As a result, the effective components of the medicinal materials of the radix astragali, including astragalus polysaccharides and total saponin, and the like, are reserved in the radix astragali particle as much as possible, thus greatly improving the content of the effective components so as to improve the clinical effectiveness of the raidx astragali. Meanwhile, production period is greatly shortened; energy consumption is decreased; and cost is lowered. The invention also provides a quality control method of the raidx astragali particle.

Apparatus and methods for quick acute and chronic pain suppression, particularly useful and effective towards high-grade pains and / or pains resistant to other analgesic drugs such as opiates. One apparatus and method generate synthetic “non-pain” information strings of great clinical effectiveness, allowing high reproducibility of the clinical result. Synthesis of the strings occurs by combining novel geometries of complex waveforms in a sequence, perceived as “self” and “non-pain” by the CNS.

The invention belongs to the field of medicine, and particularly relates to cardiac failure resisting medicine LCZ696 oral sustained-release pellets and a preparation method thereof. The sustained-release pellets comprise pellet cores prepared from, by weight, 2-55 parts of LCZ696 medicine, 15-90 parts of diluent and 1-15 parts of adhesive and a coating prepared from, by weight, 1-35 parts of sustained-release materials, 0.1-5 parts of pore-foaming agent, 0.1-5 parts of plasticizer and 0.1-25 parts of antisticking agent on the outer portions of the pellet cores. The cardiac failure resisting medicine LCZ696 oral sustained-release pellets have the advantages that LCZ696 can be slowly released in the body by means of the sustained-release pellets, the plasma concentration is more stable, and clinical effectiveness and safety are effectively improved. The cardiac failure resisting medicine LCZ696 oral sustained-release pellets are suitable for symptoms caused by the cardiac failure, medicine release is stable, the effect is good, irritation to the gastrointestinal tract is small, and absorption is good after oral medication. The preparation method of the sustained-release pellets is easy to operate, the production cost is low, efficiency is high, and the sustained-release pellets are suitable for large-scale production.

The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and / or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.

The invention discloses a method and system for clinical effectiveness evaluation of artificial intelligence based medical devices. The clinical effectiveness evaluation system includes a diagnosis result receiving unit receiving diagnosis results for arbitrary clinical data from a plurality of specialists and the artificial intelligence based medical device; a correspondence degree calculation unit calculating a degree of correspondence between the received diagnosis results; a statistical value derivation unit deriving a predetermined statistical value on the basis of the calculated degree of correspondence; and a comparison test unit performing a comparison test on the artificial intelligence based medical device using the derived statistical value.

The invention relates to an environment-friendly production process for high-purity montmorillonite. The production process comprises the following steps: (1) drying, soaking, dispersing and sieving a bentonite raw material to obtain a crude solution of montmorillonite; (2) performing ultrasonic dispersion on the crude solution to obtain suspended emulsion; (3) performing cyclone separation on the suspended emulsion to remove a material with the relative density of more than 2.5g / cm<3>, sieving, standing, and removing water on the upper layer to obtain a material on the lower layer; (4) performing high temperature and high pressure cooperative ultrasonic sterilization on the material on the lower layer to obtain a sterilized material; and (5) performing centrifugal separation on the sterilized material, collecting a material with the relative density of less than or equal to 2.5g / cm<3>, drying, grinding until the average grain diameter of less than or equal to 45mu m, and sieving by using a 325-400-mesh sieve to obtain the montmorillonite. The environment-friendly production process ensures medication safety, clinical effectiveness and controlled quality, the process is simple and environment-friendly, the production efficiency is high, the production cost is low, the product quality is high, and industrial montmorillonite production is easily realized; and high temperature, high pressure and ultrasonic waves are combined for sterilization to ensure safety, reliability and a good sterilization effect.